Raymond James Projects 'Rising Momentum' At Catalent Driven By Biologics Expansion

By: via Benzinga
Catalent, Inc. (NYSE: CTLT)’s plans for expansion of its biologics segment are likely to bring the stock back after weak ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.